Technology & Science
Sep. 7, 2010
Allergan's Botox Settlement Bodes Ill
The $600 million in fines that Irvine-based Allergan Inc. must pay for off-label promotion of Botox may be a shot in the arm for plaintiffs who claim they were harmed by injections of the drug.
Daily Journal Staff Writer
The $600 million in fines that Irvine-based Allergan Inc. must pay for marketing Botox to doctors for unapproved uses may be a shot in the arm for plaintiffs who claim they were harmed by the drug.
Allergan and the U.S. Department of Justice announced a settlement Sept. 1 in which the company pleaded guilty to one misdemeanor charge of misbranding and agreed to pay a $375 million cri...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In